Type II Diabetes: Clinical Trials

65 trials for Type II Diabetes, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

39 completed, 16 unknown, 4 recruiting, 3 terminated. 24 Not applicable, 14 Phase 1, 6 Phase 4, 3 Phase 2, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Not applicable24Completed 16, Unknown 6, Active not recruiting 1, Recruiting 1
Phase 114Completed 10, Unknown 4
Phase 46Terminated 2, Completed 1, Not yet recruiting 1, Recruiting 1, Unknown 1
Phase 23Completed 2, Withdrawn 1
Phase 33Completed 2, Recruiting 1
Early Phase 12Terminated 1, Unknown 1

Follow Type II Diabetes: new trials by email Literature Review of Type II Diabetes trials Research Report on Type II Diabetes

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Heart-Kidney-Diabetes Multidisciplinary Care MOdels for CardiovascuLar Health In Patients With Chronic Kidney DiSease and Diabetes: A PragmaTIC Cluster Randomized Controlled Trial (HOLISTIC)
The intervention with the MCM is Kidney-Heart GDMT initiation and titration for dose optimization (as clinically tolerated), within 4 months of enrollment in the study. - Chronic Kidney Disease, Type II Diabetes
Phase 4Not yet recruitingBaim Institute for Clinical Research5702026-12-012026-09-10
The GRoceries Aimed at Increasing Nutrition Study
Marketing Nudges Only, Marketing Nudges + Dynamically Adapted Financial Incentives - Type 2 Diabetes, Type II Diabetes Mellitus
Not applicableActive not recruitingUniversity of Pennsylvania2192025-10-142026-10-20
Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients
Lifestyle counseling and coaching - Obesity, Hyperlipidemias
Not applicableRecruitingWest Virginia School of Osteopathic Medicine952025-02-012025-07-25
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
PIEMONTE, PIEMONTE PLACEBO, EMPAGLIFLOZIN - Type II Diabetes
Phase 3RecruitingEMS4802024-10-082025-12-08
Effectiveness of an mHealth Mobile App
mobile app use - Type II Diabetes
Not applicableUnknownDow University of Health Sciences1602024-03-202024-04-30
Passive Stretching Versus Electrical Stimulation on Glucose Level, in Elderly With Type II Diabetes
passive stretching for group A, electrical stimulation for group b - Type II Diabetes
Not applicableUnknownMona Mohamed Abdelkhalek602024-02-102024-02-07
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
Tirzepatide, Placebo - Type II Diabetes, Atherosclerosis
Phase 4RecruitingMatthew J. Budoff1202024-01-022024-10-15
Safety, Pharmacokinetics, and Food Effect of PS1 in Subjects
PS1, Placebo - Type II Diabetes
Phase 1CompletedPharmasaga Co. Ltd.752023-12-222026-07-07
The Effects of Raspberry Leaf Tea on Blood Glucose Control
Raspberry leaf tea - Type II Diabetes
Not applicableUnknownUniversity of Reading202023-12-182024-04-26
Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150, D029 in Healthy Adults
CKD-378 (low-dose) - Type II Diabetes
Phase 1CompletedChong Kun Dang Pharmaceutical232023-06-012023-12-19
A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378
CKD-378, QD, PO Drug: D745, D150, QD, PO - Type II Diabetes
Phase 1CompletedChong Kun Dang Pharmaceutical242023-04-112024-03-12
Burger Allen Exercises in Knee OA With Type II Diabetes
thermotherapy+ TENS+ low intensity high repetition exercises and Buerger Allen, thermotherapy+ TENS+ low intensity high repetition exercises - Knee Osteoarthritis, Type II Diabetes
Not applicableCompletedRiphah International University362023-03-312023-09-25
Association Between Natural Hypoglycemic Foods and Blood Sugar Level: A Pilot Study
Hypoglycemic food group, Control group - Type II Diabetes
Not applicableUnknownAntenna Foundation1242022-04-012022-03-10
A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects
T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR, T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR - Type II Diabetes
Phase 1UnknownShandong Suncadia Medicine Co., Ltd.802021-11-092021-11-04
A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers
FDC tablet - Type II Diabetes
Phase 1UnknownShandong Suncadia Medicine Co., Ltd.282021-10-132021-11-24
Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes
pratice physical activity - Type II Diabetes
Not applicableCompletedCentre Hospitalier Sud Francilien602021-10-112026-05-26
Dietary Approaches to Stop Hypertension for Diabetes
DASH4D diet, comparison diet, higher sodium - Diabetes Mellitus, Type 2, Diabetes
Not applicableCompletedJohns Hopkins University1052021-06-022026-05-13
A Study to Investigate the PK and Safety of CKD-393
CKD-393 formulation I, CKD-393 formulation II, D501, D759, H053 - Type II Diabetes
Phase 1CompletedChong Kun Dang Pharmaceutical262021-03-262021-08-02
Mass Balance and Biotransformation of [14C]HSK7653 in Human
[14C]HSK7653 - Type II Diabetes
Phase 1CompletedSichuan Haisco Pharmaceutical Group Co., Ltd62020-11-152022-12-12
Evaluation of Effects of Dibifree® on Regulation of Blood Sugar and HbA1c in Patients With Type II Diabetes
Compound plant extracts, Indigestible dextrin - Type II Diabetes
Not applicableCompletedGlobal Preventive Medicine Biotech Co., Ltd.562020-08-262025-07-16

Showing 20 of 65. Sign in to see all of them.

Narrower conditions

Diabetes Mellitus, Type 2 (65)  ·  Diabetes Mellitus (15)  ·  Obesity (6)  ·  Hypertension (5)  ·  Cardiovascular Diseases (4)  ·  Atherosclerosis (3)  ·  Chronic Disease (3)  ·  Depression (2)  ·  Dyslipidemias (2)  ·  Glucose Intolerance (2)  ·  Insulin Resistance (2)  ·  Metabolic Syndrome (2)  ·  Motor Activity (2)  ·  Patient Compliance (2)  ·  Periodontal Diseases (2)

Broader conditions

Endocrine System Diseases (65)  ·  Glucose Metabolism Disorders (65)  ·  Metabolic Diseases (65)  ·  Nutritional and Metabolic Diseases (65)  ·  Diabetes Mellitus (50)  ·  Pathological Conditions, Signs and Symptoms (13)  ·  Behavior (8)  ·  Cardiovascular Diseases (8)  ·  Pathologic Processes (8)  ·  Signs and Symptoms (8)  ·  Vascular Diseases (7)  ·  Body Weight (6)  ·  Disease Attributes (6)  ·  Nutrition Disorders (6)  ·  Overnutrition (6)

Interventions

Metformin (6)  ·  AZD1656 (2)  ·  Amiloride (2)  ·  Pioglitazone (2)  ·  Sitagliptin Phosphate (2)  ·  empagliflozin (2)  ·  Atorvastatin (1)  ·  Blood Specimen Collection (1)  ·  Control Groups (1)  ·  Dental Prophylaxis (1)  ·  Diet (1)  ·  Dipeptidyl-Peptidase IV Inhibitors (1)  ·  Early Intervention, Educational (1)  ·  Electric Stimulation (1)  ·  Glucagon-Like Peptide-1 Receptor Agonists (1)

Sponsors

Chong Kun Dang Pharmaceutical (4)  ·  AstraZeneca (3)  ·  Duke University (2)  ·  Johns Hopkins Bloomberg School of Public Health (2)  ·  Shandong Suncadia Medicine Co., Ltd. (2)  ·  Antenna Foundation (1)  ·  Aristotle University Of Thessaloniki (1)  ·  Baim Institute for Clinical Research (1)  ·  Boston Therapeutics (1)  ·  Brigham and Women's Hospital (1)  ·  Centre Hospitalier Sud Francilien (1)  ·  Centre Hospitalier Universitaire Dijon (1)  ·  Centre Hospitalier Universitaire de Nīmes (1)  ·  Daewoong Pharmaceutical Co. LTD. (1)  ·  Dow University of Health Sciences (1)

Countries

United States (28)  ·  France (6)  ·  South Korea (6)  ·  China (3)  ·  Taiwan (3)  ·  Canada (2)  ·  Egypt (2)  ·  Pakistan (2)  ·  Brazil (1)  ·  Chile (1)  ·  Finland (1)  ·  Greece (1)  ·  Ireland (1)  ·  Netherlands (1)  ·  United Kingdom (1)

Top investigators

John Bridges, PhD (2)  ·  Bertrand Graz, MD, MPH (1)  ·  Christopher L Pankey, Ph.D. (1)  ·  David Costa, MD (1)  ·  Deborah Cohen, PhD (1)  ·  Elizabeth Selvin, PhD (1)  ·  Emanuel P DeNoia, M.D (1)  ·  George Ferzli, MD (1)  ·  Hakcheol Jang, M.D., Ph.D. (1)  ·  Howard Nathan, MD (1)  ·  Hsin Chieh Yeh, PhD (1)  ·  Isaac Lipkus (1)  ·  Jack L Martin, MD (1)

Results publications

PMID 23890106, PMID 23920034, PMID 25072436, PMID 26446491, PMID 26597630, PMID 27519448, PMID 29263572, PMID 30222367, PMID 32006325, PMID 32437409, PMID 32482202, PMID 32501595, PMID 33097036, PMID 33382877, PMID 33427191, PMID 35229613, PMID 35868830, PMID 37733885, PMID 38191968, PMID 38646838, PMID 38978010, PMID 39900263, PMID 40489102, PMID 40764427, PMID 41553854, PMID 41744113, PMID 41992221

NIH funding

F31NR017813 (1), P30AG034546 (1), R01DK128900 (1), R34DK124146 (1)